Pharmaceutical Contract Manufacturing Market by Service (Drug Development, Pharmaceutical (API, FDF - Parenteral, Tablet, Capsule), Biologics (API, FDF), Packaging & Labelling, Fill-finish), Molecule (Small, Large (ADC, CGT)) - Global Forecast to 2030

icon1
USD 311.95 BN
MARKET SIZE, 2030
icon2
CAGR 8.2%
(2025-2030)
icon3
527
REPORT PAGES
icon4
620
MARKET TABLES

OVERVIEW

pharmaceutical-contract-manufacturing-market Overview

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

The global pharmaceutical contract manufacturing market is estimated to be USD 209.90 billion in 2025 and reach USD 311.95 billion by 2030, with a CAGR of 8.2% from 2025 to 2030. The pharmaceutical contract manufacturing market is expected to get a boost due to the GLP-1 capacity crunch, the increase in ADC development, the loss of patent expiries, and the increase in demand for biosimilars.

KEY TAKEAWAYS

  • By Region
    The North America peptide synthesis market accounted for a 40.3% revenue share in 2024.
  • By Services
    By Services, the drug development services segment is expected to register the highest CAGR of 12.2%.
  • By Molecule
    By Molecule, the large molecule segment will grow the fastest during the forecast period.
  • By End user
    By end user, the big pharmaceutical companies segment is expected to dominate the market, growing at the highest CAGR of 8.7%.
  • competitive landscape
    Thermo Fisher Scientific Inc, Lonza , Catalent, Inc were identified as some of the star players in the cell counting market (global), given their strong market share and product footprint.

The pharmaceutical contract manufacturing market is undergoing a significant transformation driven by advancements in technology, evolving regulatory frameworks, and shifting client demands. The adoption of continuous manufacturing, single-use bioreactor systems, and advanced process analytics is enabling greater efficiency, scalability, and cost-effectiveness in drug production. The rise of cell and gene therapies is prompting CDMOs to invest in specialized viral vector manufacturing, automated fill-finish systems, and high-containment facilities to meet stringent quality and biosafety standards

TRENDS & DISRUPTIONS IMPACTING CUSTOMERS' CUSTOMERS

The pharmaceutical contract manufacturing market is undergoing major transformation driven by rapid expansion of biologics, sterile injectables, and advanced therapies. Rising complexity in drug pipelines, demand for speed-to-market, and pressure to lower production costs are accelerating the shift toward outsourced GMP manufacturing. At the same time, evolving regulatory expectations for data integrity, quality consistency, and global supply chain resilience are reshaping CDMO operations. Technology disruptions such as continuous manufacturing, single-use bioprocessing, automation, and AI-driven quality control are enabling faster scale-up, higher batch reliability, and reduced production risk. These developments are pushing pharma companies toward strategic outsourcing partnerships and end-to-end CDMO solutions, driving demand for next-generation contract manufacturing capabilities.

pharmaceutical-contract-manufacturing-market Disruptions

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

MARKET DYNAMICS

Drivers
Impact
Level
  • GLP-1 capacity crunch
  • Increasing development and manufacturing of antibody drug conjugates
RESTRAINTS
Impact
Level
  • Pricing pressure on innovator drugs
  • Growing penetration of generics and biosimilars
OPPORTUNITIES
Impact
Level
  • Rising demand for cell and gene therapies
  • Growing inclination toward one-stop-shop model
CHALLENGES
Impact
Level
  • Global trade instability and insourcing

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

Driver: GLP-1 capacity crunch

Growing global demand for GLP-1 drugs is creating a significant manufacturing capacity crunch, pushing pharmaceutical companies to rely heavily on CDMOs. Limited in-house biologics and peptide production capabilities, long scale-up timelines, and supply pressures are driving outsourced GMP manufacturing to ensure continuous supply and rapid market expansion.

Restraint: Pricing pressure on innovator drugs

Intensifying pricing pressure on innovative drugs is driving pharmaceutical companies to seek cost-efficient manufacturing models, accelerating reliance on CDMOs. As payers demand lower prices and governments tighten reimbursement, drug makers increasingly outsource production to reduce operational costs, optimize supply chains, and maintain profitability across high-value therapeutic portfolios.

Opportunity: Rising demand for cell and gene therapies

Rising demand for cell and gene therapies presents a major opportunity for the pharmaceutical CDMO market. As advanced therapies require specialized GMP facilities, viral vector capacity, and complex manufacturing expertise, drug developers increasingly depend on CDMOs to scale production. This surge enables CDMOs to expand high-value capabilities and secure long-term strategic partnerships.

Challenge:Global trade instability and insourcing

Global trade instability is creating a challenge for the pharmaceutical CDMO market, disrupting supply chains for APIs, raw materials, and critical components. Fluctuating tariffs, geopolitical tensions, and import–export restrictions increase production risks and costs, pushing companies to reassess sourcing strategies, diversify manufacturing partners, and strengthen regional CDMO networks.

pharmaceutical-contract-manufacturing-market: COMMERCIAL USE CASES ACROSS INDUSTRIES

COMPANY USE CASE DESCRIPTION BENEFITS
AstraZeneca partners with WuXi Biologics for commercial-scale manufacturing of monoclonal antibodies and biologics to meet global demand for oncology and respiratory therapies. Secures large-volume, multi-site commercial supply and ensures rapid global distribution in high-demand market
Eli Lilly uses Cipla’s India-based CDMO facilities for commercial manufacturing of insulin formulations to supply emerging markets at scale. Expands manufacturing capacity in cost-efficient regions and strengthens supply reliability for chronic disease therapies.
Teva relies on Recipharm for commercial production of inhalation and respiratory medicines, using Recipharm’s specialized device-plus-drug manufacturing expertise Access to advanced inhalation device technology and faster commercial rollout for complex combination products

Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.

MARKET ECOSYSTEM

The pharmaceutical CDMO market ecosystem consists of API and finished-dosage manufacturers (Catalent, Lonza), biologics and advanced therapy CDMOs (Samsung Biologics, WuXi Biologics), and specialized service providers for sterile injectables, HPAPIs, and cell & gene therapy production. These players supply end-to-end development, scale-up, and GMP manufacturing services supporting pharma, biotech, generics, and virtual pharma companies. Demand is driven by complex drug pipelines, rising biologics production needs, and the shift toward outsourcing to reduce cost and accelerate time-to-market. Collaboration across CDMOs, technology providers, and drug developers enables advances in automation, single-use bioprocessing, digital quality systems, and global supply resilience, supporting the market’s expansion and transition toward integrated, high-value manufacturing partnerships.

pharmaceutical-contract-manufacturing-market Ecosystem

Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.

MARKET SEGMENTS

pharmaceutical-contract-manufacturing-market Segments

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

Pharmaceutical Contract Manufacturing Market, By Service

As of 2024, pharmaceutical manufacturing services account for the largest share of the pharmaceutical CDMO market and are expected to maintain this lead through 2025. This dominance is driven by rising demand for large-scale GMP production of APIs, biologics, sterile injectables, and complex formulations. Unlike development services, manufacturing requires significant capacity, specialized facilities, and long-term commercial supply agreements, ensuring consistent revenue. The accelerating shift toward outsourcing and the growing volume of biologics and high-potency drugs further reinforce manufacturing services as the core revenue-generating segment of the CDMO market.

Pharmaceutical Contract Manufacturing Market, By Molecule

As of 2024, large molecules dominate the molecule segment of the pharmaceutical CDMO market and are expected to maintain their lead through 2025. Growing demand for biologics, monoclonal antibodies, and advanced therapies requires specialized GMP facilities, high-complexity manufacturing, and significant capacity investments—capabilities increasingly sourced from CDMOs. The rapid expansion of biologics pipelines and rising outsourcing by pharma and biotech companies further reinforce large molecules as the leading and fastest-growing segment.

Pharmaceutical Contract Manufacturing Market, By End User

As of 2024, big pharmaceutical companies dominate the end-user segment of the pharmaceutical CDMO market and are expected to maintain their lead through 2025. Their dominance is driven by the large volume of commercial-scale production they outsource, growing biologics and injectable portfolios, and the need to optimize cost, capacity, and supply chain resilience. Strategic partnerships, long-term manufacturing contracts, and expansion into complex modalities further reinforce big pharma as the largest and most influential end-user group in the CDMO ecosystem.

REGION

Asia Pacific to be fastest-growing region in global pharmaceutical contract manufacturing market during forecast period

The Asia Pacific pharmaceutical CDMO market is projected to grow at the fastest rate during the forecast period, driven by rapid expansion in biopharmaceutical production, sterile injectable manufacturing, and advanced therapy capabilities. Countries such as China, India, South Korea, and Singapore are heavily investing in GMP facilities, automation, and large-scale biologics and API manufacturing infrastructure. Rising clinical trial activity, government support for pharmaceutical innovation, and the strong presence of cost-efficient CDMOs make the region an attractive outsourcing hub for global pharma. These developments collectively position Asia Pacific as the fastest-growing region in the global CDMO market.

pharmaceutical-contract-manufacturing-market Region

pharmaceutical-contract-manufacturing-market: COMPANY EVALUATION MATRIX

In the pharmaceutical CDMO market matrix, Thermo Fisher Scientific (Star) leads with a strong market share and an extensive end-to-end service portfolio spanning API manufacturing, biologics, sterile injectables, cell and gene therapy, and commercial-scale supply. Its global GMP network, advanced technologies, and integrated development-to-manufacturing capabilities position it as the preferred partner for both large pharma and emerging biotech companies.Cambrex corporation (Emerging Leader) is steadily gaining traction by expanding its specialized strengths in small-molecule API manufacturing, oral solid dose development, and clinical-to-commercial supply solutions. While Thermo Fisher maintains dominance through scale, diversification, and global infrastructure, Almac shows strong potential to move toward the leaders quadrant as demand rises for high-quality, flexible, and specialized CDMO services.

pharmaceutical-contract-manufacturing-market Evaluation Metrics

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

KEY MARKET PLAYERS

MARKET SCOPE

REPORT METRIC DETAILS
Market Size in 2024 (Value) USD 193.52 Billion
Market Forecast in 2030 (Value) USD 311.95 Billion
Growth Rate CAGR of 8.2% from 2025-2030
Years Considered 2023-2030
Base Year 2024
Forecast Period 2025-2030
Units Considered Value (USD Billion)
Report Coverage Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Segments Covered
  • By Services :
    • Pharmaceutical Manufacturing Services
    • Drug Development Services
    • Biologics Manufacturing Services
    • Packaging & Labelling Services
    • Fill-finish Services
    • Other Services
  • By Molecules:
    • Small molecules
    • Large Molecules
  • By end users:
    • Big pharmaceutical companies
    • Small & medium-sized pharmaceutical companies
    • Generic pharmaceutical companies
    • Others (Academic Institutes
    • CROs)
Regions Covered North America, Asia Pacific, Europe, South America, Middle East and Africa

WHAT IS IN IT FOR YOU: pharmaceutical-contract-manufacturing-market REPORT CONTENT GUIDE

pharmaceutical-contract-manufacturing-market Content Guide

DELIVERED CUSTOMIZATIONS

We have successfully delivered the following deep-dive customizations:

CLIENT REQUEST CUSTOMIZATION DELIVERED VALUE ADDS
Capacity & Capability Mapping Detailed mapping of CDMO manufacturing capacity by API type, biologics, HPAPI, sterile injectables, and advanced therapies Improves supply planning and reduces outsourcing risks
Supply Chain & Risk Assessment Mapping of supply chain vulnerabilities including API sourcing, geopolitics, and logistics bottlenecks Strengthens business continuity planning

RECENT DEVELOPMENTS

  • October 2024 : Thermo Fisher Scientific Inc. launched accelerator drug development, which offered an end-to-end suite of drug development and clinical services spanning drug substance and drug product manufacturing for small molecule, large molecule, and advanced therapies, clinical supply, clinical research, and commercialization.
  • March 2024 : Lonza acquired theGenentech large-scale biologics manufacturing site in Vacaville, California (US) from Roche.
  • June 2023 : Lonza and Vertex collaborated to support the manufacture of Vertex's portfolio of investigational stem cell- derived, fully differentiated insulin-producing islet cell therapies for people with T1D, currently focusing on the VX- 880 and VX-264 programs that are in clinical trials.

 

Table of Contents

Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.

TITLE
PAGE NO
1
INTRODUCTION
 
 
 
42
2
RESEARCH METHODOLOGY
 
 
 
47
3
EXECUTIVE SUMMARY
 
 
 
60
4
PREMIUM INSIGHTS
 
 
 
66
5
MARKET OVERVIEW
Navigate market shifts as biologic drug complexity and generics disrupt pricing and production.
 
 
 
71
 
5.1
INTRODUCTION
 
 
 
 
5.2
MARKET DYNAMICS
 
 
 
 
 
5.2.1
DRIVERS
 
 
 
 
 
5.2.1.1
GLP-1 CAPACITY CRUNCH
 
 
 
 
5.2.1.2
INCREASING DEVELOPMENT AND MANUFACTURING OF ANTIBODY DRUG CONJUGATES
 
 
 
 
5.2.1.3
LOSS OF EXCLUSIVITY OF BLOCKBUSTER BIOLOGICS
 
 
 
 
5.2.1.4
INCREASING COMPLEXITY OF INJECTABLE DRUG FORMATS
 
 
 
5.2.2
RESTRAINTS
 
 
 
 
 
5.2.2.1
PRICING PRESSURE ON INNOVATOR DRUGS
 
 
 
 
5.2.2.2
GROWING PENETRATION OF GENERICS AND BIOSIMILARS
 
 
 
 
5.2.2.3
STRICT REGULATORY COMPLIANCE
 
 
 
 
5.2.2.4
RISK IN ADVANCED THERAPIES PIPELINE
 
 
 
5.2.3
OPPORTUNITIES
 
 
 
 
 
5.2.3.1
RISING DEMAND FOR CELL AND GENE THERAPIES
 
 
 
 
5.2.3.2
GROWING INCLINATION TOWARD ONE-STOP-SHOP MODEL
 
 
 
 
5.2.3.3
MARKET EXPANSION IN EMERGING COUNTRIES
 
 
 
 
5.2.3.4
BOOMING RADIOPHARMACEUTICAL AND NUCLEAR MEDICINE SEGMENT
 
 
 
5.2.4
CHALLENGES
 
 
 
 
 
5.2.4.1
GLOBAL TRADE INSTABILITY AND INSOURCING
 
 
5.3
TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
 
 
 
 
5.4
PRICING ANALYSIS
 
 
 
 
 
 
5.4.1
INDICATIVE PRICING ANALYSIS, BY SERVICE
 
 
 
 
5.4.2
INDICATIVE PRICING ANALYSIS, BY REGION
 
 
 
 
5.4.3
COMPARISON OF CDMO PRICING MODELS
 
 
 
5.5
VALUE CHAIN ANALYSIS
 
 
 
 
 
5.6
SUPPLY CHAIN ANALYSIS
 
 
 
 
 
5.7
ECOSYSTEM ANALYSIS
 
 
 
 
 
 
5.7.1
MANUFACTURING SITE, EXPANSION, AND CAPEX TREND OF KEY CDMOS
 
 
 
5.8
INVESTMENT AND FUNDING SCENARIO
 
 
 
 
5.9
TECHNOLOGY ANALYSIS
 
 
 
 
 
5.9.1
KEY TECHNOLOGIES
 
 
 
 
 
5.9.1.1
SINGLE-USE BIOPROCESSING SYSTEMS
 
 
 
 
5.9.1.2
CONTINUOUS MANUFACTURING
 
 
 
 
5.9.1.3
ADVANCED FORMULATION TECHNOLOGIES
 
 
 
5.9.2
COMPLEMENTARY TECHNOLOGIES
 
 
 
 
 
5.9.2.1
HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY
 
 
 
 
5.9.2.2
MASS SPECTROMETRY
 
 
 
 
5.9.2.3
NEXT-GENERATION SEQUENCING
 
 
 
 
5.9.2.4
AUTOMATION AND ROBOTICS
 
 
 
 
5.9.2.5
PROCESS ANALYTICAL TECHNOLOGY
 
 
 
5.9.3
ADJACENT TECHNOLOGIES
 
 
 
 
 
5.9.3.1
3D PRINTING
 
 
 
 
5.9.3.2
ARTIFICIAL INTELLIGENCE AND MACHINE LEARNING
 
 
5.10
PATENT ANALYSIS
 
 
 
 
 
5.11
KEY CONFERENCES AND EVENTS, 2025–2026
 
 
 
 
5.12
REGULATORY LANDSCAPE
 
 
 
 
 
5.12.1
REGULATORY SCENARIO
 
 
 
 
5.12.2
REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
 
 
 
5.13
PORTER’S FIVE FORCES ANALYSIS
 
 
 
 
 
5.13.1
BARGAINING POWER OF SUPPLIERS
 
 
 
 
5.13.2
BARGAINING POWER OF BUYERS
 
 
 
 
5.13.3
THREAT OF NEW ENTRANTS
 
 
 
 
5.13.4
THREAT OF SUBSTITUTES
 
 
 
 
5.13.5
INTENSITY OF COMPETITIVE RIVALRY
 
 
 
5.14
KEY STAKEHOLDERS AND BUYING CRITERIA
 
 
 
 
 
 
5.14.1
KEY STAKEHOLDERS IN BUYING PROCESS
 
 
 
 
5.14.2
BUYING CRITERIA
 
 
 
5.15
UNMET NEEDS OF END USERS
 
 
 
 
 
5.15.1
CAPACITY AND TIMELY ACCESS
 
 
 
 
5.15.2
COST EFFICIENCY AND FLEXIBILITY
 
 
 
 
5.15.3
END-TO-END INTEGRATED SERVICES
 
 
 
 
5.15.4
ADVANCED MODALITY EXPERTISE
 
 
 
 
5.15.5
QUALITY AND REGULATORY CONSISTENCY
 
 
 
5.16
ABBREVIATED NEW DRUG APPLICATION (ANDA) APPROVALS
 
 
 
 
5.17
IMPACT OF AI/GEN AI ON PHARMACEUTICAL CONTRACT MANUFACTURING MARKET
 
 
 
 
 
 
5.17.1
INTRODUCTION
 
 
 
 
5.17.2
MARKET POTENTIAL OF AI/GEN AI
 
 
 
 
5.17.3
AI USE CASES
 
 
 
 
5.17.4
KEY COMPANIES IMPLEMENTING AI/GEN AI
 
 
 
5.18
IMPACT OF 2025 US TARIFFS ON PHARMACEUTICAL CONTRACT MANUFACTURING MARKET
 
 
 
 
 
 
5.18.1
INTRODUCTION
 
 
 
 
5.18.2
KEY TARIFF RATES
 
 
 
 
5.18.3
PRICE IMPACT ANALYSIS
 
 
 
 
5.18.4
IMPACT ON COUNTRY/REGION
 
 
 
 
 
5.18.4.1
US
 
 
 
 
5.18.4.2
EUROPE
 
 
 
 
5.18.4.3
ASIA PACIFIC
 
 
 
5.18.5
IMPACT ON END-USE INDUSTRIES
 
 
6
PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE
Market Size & Growth Rate Forecast Analysis to 2030 in USD Billion | 116 Data Tables
 
 
 
126
 
6.1
INTRODUCTION
 
 
 
 
6.2
PHARMACEUTICAL MANUFACTURING SERVICES
 
 
 
 
 
6.2.1
PHARMACEUTICAL API MANUFACTURING SERVICES
 
 
 
 
 
6.2.1.1
RISING CASES OF PATENT EXPIRY TO FUEL MARKET
 
 
 
6.2.2
PHARMACEUTICAL FDF MANUFACTURING SERVICES
 
 
 
 
 
6.2.2.1
PARENTERAL MANUFACTURING SERVICES
 
 
 
 
6.2.2.2
TABLET MANUFACTURING SERVICES
 
 
 
 
6.2.2.3
CAPSULE MANUFACTURING SERVICES
 
 
 
 
6.2.2.4
ORAL LIQUID MANUFACTURING SERVICES
 
 
 
 
6.2.2.5
SEMI-SOLID MANUFACTURING SERVICES
 
 
 
 
6.2.2.6
OTHER FDF MANUFACTURING SERVICES
 
 
6.3
DRUG DEVELOPMENT SERVICES
 
 
 
 
 
6.3.1
INCREASING COST OF DRUG DISCOVERY AND DEVELOPMENT TO EXPEDITE GROWTH
 
 
 
6.4
BIOLOGICS MANUFACTURING SERVICES
 
 
 
 
 
6.4.1
BIOLOGICS API MANUFACTURING SERVICES
 
 
 
 
 
6.4.1.1
RISING INVESTMENTS IN SINGLE-USE PRODUCTION CAPACITIES TO BOLSTER GROWTH
 
 
 
6.4.2
BIOLOGICS FDF MANUFACTURING SERVICES
 
 
 
 
 
6.4.2.1
GROWING DEMAND FOR GENERIC MEDICINES AND BIOLOGICS TO FUEL MARKET
 
 
6.5
PACKAGING & LABELING SERVICES
 
 
 
 
 
6.5.1
INCREASING COMPLEXITY AND STRINGENCY OF REGULATORY REQUIREMENTS FOR DRUG SAFETY AND EFFICACY TO FAVOR GROWTH
 
 
 
6.6
FILL-FINISH SERVICES
 
 
 
 
 
6.6.1
SURGE IN DEMAND FOR BIOLOGICS AND COMPLEX INJECTABLE THERAPIES TO BOOST MARKET
 
 
 
6.7
OTHER SERVICES
 
 
 
7
PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE
Market Size & Growth Rate Forecast Analysis to 2030 in USD Billion | 87 Data Tables
 
 
 
185
 
7.1
INTRODUCTION
 
 
 
 
7.2
SMALL MOLECULES
 
 
 
 
 
7.2.1
HIGH-POTENCY SMALL MOLECULES
 
 
 
 
 
7.2.1.1
INCREASING ADOPTION OF HIGH-POTENCY SMALL MOLECULES FOR TREATING ONCOLOGY, RARE DISEASES, AND OTHER DISEASES TO AID GROWTH
 
 
 
7.2.2
OLIGONUCLEOTIDE & SYNTHETIC PEPTIDES
 
 
 
 
 
7.2.2.1
GROWING FOCUS ON NEXT-GEN THERAPIES TO DRIVE MARKET
 
 
 
7.2.3
RADIOPHARMACEUTICAL MOLECULES
 
 
 
 
 
7.2.3.1
ADVANCES IN ISOTOPE PRODUCTION, RADIOLABELING CHEMISTRY, AND THERANOSTIC APPROACHES TO BOOST MARKET
 
 
 
7.2.4
OTHER SMALL MOLECULES
 
 
 
7.3
LARGE MOLECULES
 
 
 
 
 
7.3.1
MONOCLONAL ANTIBODIES
 
 
 
 
 
7.3.1.1
RISING USE OF MABS IN MANAGING CANCER, AUTOIMMUNE DISORDERS, AND OSTEOPOROSIS TO SPUR GROWTH
 
 
 
7.3.2
CELL & GENE THERAPIES
 
 
 
 
 
7.3.2.1
EMERGING TREATMENTS FOR PREVIOUSLY UNTREATABLE GENETIC AND RARE DISEASES TO BOOST MARKET
 
 
 
7.3.3
ANTIBODY DRUG CONJUGATES
 
 
 
 
 
7.3.3.1
GROWING NEED FOR PRECISION MEDICINES TO FUEL MARKET
 
 
 
7.3.4
VACCINES
 
 
 
 
 
7.3.4.1
GROWING THREAT OF INFECTIOUS DISEASE OUTBREAKS TO DRIVE MARKET
 
 
 
7.3.5
THERAPEUTIC PEPTIDES & PROTEINS
 
 
 
 
 
7.3.5.1
INCREASING RESEARCH IN GENOMICS TO SUPPORT GROWTH
 
 
 
7.3.6
OTHER LARGE MOLECULES
 
 
8
PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER
Market Size & Growth Rate Forecast Analysis to 2030 in USD Billion | 29 Data Tables
 
 
 
229
 
8.1
INTRODUCTION
 
 
 
 
8.2
BIG PHARMACEUTICAL COMPANIES
 
 
 
 
 
8.2.1
PRICING PRESSURE IN PHARMACEUTICAL INDUSTRY TO CONTRIBUTE TO GROWTH
 
 
 
8.3
SMALL & MEDIUM-SIZED PHARMACEUTICAL COMPANIES
 
 
 
 
 
8.3.1
NEED TO SAVE IN-HOUSE DRUG MANUFACTURING COST TO FOSTER GROWTH
 
 
 
8.4
GENERIC PHARMACEUTICAL COMPANIES
 
 
 
 
 
8.4.1
FAVORABLE GOVERNMENT SUPPORT FOR ADOPTION OF GENERIC DRUGS TO PROPEL MARKET
 
 
 
8.5
OTHER END USERS
 
 
 
9
PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY REGION
Comprehensive coverage of 7 Regions with country-level deep-dive of 17 Countries | 253 Data Tables.
 
 
 
245
 
9.1
INTRODUCTION
 
 
 
 
9.2
NORTH AMERICA
 
 
 
 
 
9.2.1
MACROECONOMIC OUTLOOK FOR NORTH AMERICA
 
 
 
 
9.2.2
US
 
 
 
 
 
9.2.2.1
HIGH CLINICAL TRIAL AND DRUG DISCOVERY ACTIVITIES TO FOSTER GROWTH
 
 
 
9.2.3
CANADA
 
 
 
 
 
9.2.3.1
FAVORABLE GOVERNMENT SUPPORT AND INCREASED FOCUS ON R&D ACTIVITIES TO SUSTAIN GROWTH
 
 
9.3
EUROPE
 
 
 
 
 
9.3.1
MACROECONOMIC OUTLOOK FOR EUROPE
 
 
 
 
9.3.2
GERMANY
 
 
 
 
 
9.3.2.1
FREE DRUG-PRICING POLICY AND HIGH PHARMACEUTICAL INVESTMENTS TO SPEED UP GROWTH
 
 
 
9.3.3
UK
 
 
 
 
 
9.3.3.1
FAVORABLE R&D FUNDING SCENARIO TO AUGMENT GROWTH
 
 
 
9.3.4
FRANCE
 
 
 
 
 
9.3.4.1
BOOMING LIFE SCIENCE RESEARCH AND GROWING GENERICS MARKET TO DRIVE MARKET
 
 
 
9.3.5
ITALY
 
 
 
 
 
9.3.5.1
RISING COMMERCIAL DRUG DEVELOPMENT AND INCREASING LIFE SCIENCE R&D TO FAVOR GROWTH
 
 
 
9.3.6
SWITZERLAND
 
 
 
 
 
9.3.6.1
RAPID GROWTH AS GLOBAL PHARMACEUTICAL MANUFACTURING HUB TO DRIVE MARKET
 
 
 
9.3.7
POLAND
 
 
 
 
 
9.3.7.1
UNIVERSAL HEALTH COVERAGE AND ADVANCED GOVERNMENT-SUPPORTED MEDICAL INFRASTRUCTURE TO ENCOURAGE GROWTH
 
 
 
9.3.8
SPAIN
 
 
 
 
 
9.3.8.1
GROWING PHARMACEUTICAL R&D EXPENDITURE AND INCREASING OUTSOURCING OF TRIAL PHASES TO BOOST MARKET
 
 
 
9.3.9
REST OF EUROPE
 
 
 
9.4
ASIA PACIFIC
 
 
 
 
 
9.4.1
MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
 
 
 
 
9.4.2
CHINA
 
 
 
 
 
9.4.2.1
MADE IN CHINA 2025 INITIATIVE AND HIGH GOVERNMENT DRUG DEVELOPMENT INVESTMENTS TO AID GROWTH
 
 
 
9.4.3
JAPAN
 
 
 
 
 
9.4.3.1
HIGH GERIATRIC POPULATION AND ADVANCED PHARMACEUTICAL RESEARCH TO AUGMENT GROWTH
 
 
 
9.4.4
SOUTH KOREA
 
 
 
 
 
9.4.4.1
INCREASED BIOTECH INVESTMENTS AND DEVELOPED PHARMA SECTOR TO PROPEL MARKET
 
 
 
9.4.5
INDIA
 
 
 
 
 
9.4.5.1
FAVORABLE INDUSTRIAL ENVIRONMENT AND LOWER LABOR COSTS TO DRIVE MARKET
 
 
 
9.4.6
AUSTRALIA
 
 
 
 
 
9.4.6.1
STRATEGIC GEOGRAPHICAL LOCATION AND STRINGENT REGULATORY ENVIRONMENT TO FOSTER GROWTH
 
 
 
9.4.7
REST OF ASIA PACIFIC
 
 
 
9.5
LATIN AMERICA
 
 
 
 
 
9.5.1
MACROECONOMIC OUTLOOK FOR LATIN AMERICA
 
 
 
 
9.5.2
BRAZIL
 
 
 
 
 
9.5.2.1
RAPID PATIENT ENROLMENT AND INCREASED FOCUS ON ADVANCED CLINICAL TRIALS TO EXPEDITE GROWTH
 
 
 
9.5.3
MEXICO
 
 
 
 
 
9.5.3.1
SURGE IN PHARMACEUTICAL GOODS EXPORT TO PROMOTE GROWTH
 
 
 
9.5.4
REST OF LATIN AMERICA
 
 
 
9.6
MIDDLE EAST
 
 
 
 
 
9.6.1
MACROECONOMIC OUTLOOK FOR MIDDLE EAST
 
 
 
 
9.6.2
GCC COUNTRIES
 
 
 
 
 
9.6.2.1
KINGDOM OF SAUDI ARABIA (KSA)
 
 
 
 
9.6.2.2
UAE
 
 
 
 
9.6.2.3
REST OF GCC COUNTRIES
 
 
 
9.6.3
REST OF MIDDLE EAST
 
 
 
9.7
AFRICA
 
 
 
 
 
9.7.1
RISING PREVALENCE OF CHRONIC DISEASES TO FACILITATE GROWTH
 
 
 
 
9.7.2
MACROECONOMIC OUTLOOK OF AFRICA
 
 
10
COMPETITIVE LANDSCAPE
Discover the strategic moves defining market leadership in the evolving competitive landscape.
 
 
 
391
 
10.1
INTRODUCTION
 
 
 
 
10.2
KEY PLAYER STRATEGIES/RIGHT TO WIN
 
 
 
 
10.3
REVENUE SHARE ANALYSIS, 2020–2024
 
 
 
 
10.4
MARKET SHARE ANALYSIS, 2024
 
 
 
 
 
10.5
COMPANY VALUATION AND FINANCIAL METRICS
 
 
 
 
10.6
BRAND/SERVICE COMPARISON
 
 
 
 
 
10.6.1
THERMO FISHER SCIENTIFIC INC.
 
 
 
 
10.6.2
LONZA
 
 
 
 
10.6.3
WUXI BIOLOGICS AND WUXI APPTEC
 
 
 
 
10.6.4
CATALENT, INC.
 
 
 
 
10.6.5
SAMSUNG BIOLOGICS
 
 
 
10.7
COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
 
 
 
 
 
 
10.7.1
STARS
 
 
 
 
10.7.2
EMERGING LEADERS
 
 
 
 
10.7.3
PERVASIVE PLAYERS
 
 
 
 
10.7.4
PARTICIPANTS
 
 
 
 
10.7.5
COMPANY FOOTPRINT: KEY PLAYERS, 2024
 
 
 
 
 
10.7.5.1
COMPANY FOOTPRINT
 
 
 
 
10.7.5.2
REGION FOOTPRINT
 
 
 
 
10.7.5.3
SERVICE FOOTPRINT
 
 
 
 
10.7.5.4
MOLECULE FOOTPRINT
 
 
10.8
COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024
 
 
 
 
 
 
10.8.1
PROGRESSIVE COMPANIES
 
 
 
 
10.8.2
RESPONSIVE COMPANIES
 
 
 
 
10.8.3
DYNAMIC COMPANIES
 
 
 
 
10.8.4
STARTING BLOCKS
 
 
 
 
10.8.5
COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
 
 
 
 
 
10.8.5.1
DETAILED LIST OF KEY STARTUPS/SMES
 
 
 
 
10.8.5.2
COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
 
 
10.9
COMPETITIVE SCENARIO
 
 
 
 
 
10.9.1
SERVICE LAUNCHES
 
 
 
 
10.9.2
DEALS
 
 
 
 
10.9.3
EXPANSIONS
 
 
11
COMPANY PROFILES
In-depth Company Profiles of Leading Market Players with detailed Business Overview, Product and Service Portfolio, Recent Developments, and Unique Analyst Perspective (MnM View)
 
 
 
419
 
11.1
KEY PLAYERS
 
 
 
 
 
11.1.1
THERMO FISHER SCIENTIFIC INC.
 
 
 
 
 
11.1.1.1
BUSINESS OVERVIEW
 
 
 
 
11.1.1.2
SERVICES OFFERED
 
 
 
 
11.1.1.3
RECENT DEVELOPMENTS
 
 
 
 
11.1.1.4
MNM VIEW
 
 
 
11.1.2
LONZA
 
 
 
 
11.1.3
CATALENT, INC.
 
 
 
 
11.1.4
WUXI APPTEC
 
 
 
 
11.1.5
WUXI BIOLOGICS
 
 
 
 
11.1.6
SAMSUNG BIOLOGICS
 
 
 
 
11.1.7
BOEHRINGER INGELHEIM INTERNATIONAL GMBH
 
 
 
 
11.1.8
EVONIK
 
 
 
 
11.1.9
FUJIFILM HOLDINGS CORPORATION
 
 
 
 
11.1.10
ABBVIE INC.
 
 
 
 
11.1.11
SIEGFRIED HOLDING AG
 
 
 
 
11.1.12
MERCK KGAA
 
 
 
 
11.1.13
ALMAC GROUP
 
 
 
 
11.1.14
CHARLES RIVER LABORATORIES
 
 
 
 
11.1.15
ASYMCHEM INC.
 
 
 
 
11.1.16
VETTER
 
 
 
 
11.1.17
ALCAMI CORPORATION
 
 
 
 
11.1.18
EUROFINS SCIENTIFIC
 
 
 
11.2
OTHER PLAYERS
 
 
 
 
 
11.2.1
PIRAMAL PHARMA SOLUTIONS
 
 
 
 
11.2.2
SYNGENE INTERNATIONAL LIMITED
 
 
 
 
11.2.3
CAMBREX CORPORATION
 
 
 
 
11.2.4
JUBILANT PHARMANOVA LIMITED
 
 
 
 
11.2.5
YUHAN CORPORATION
 
 
 
 
11.2.6
PIERRE FABRE LABORATORIES
 
 
 
 
11.2.7
PFIZER CENTREONE
 
 
 
 
11.2.8
DELPHARM
 
 
 
 
11.2.9
FRONTAGE LABS
 
 
 
 
11.2.10
SHARP SERVICES, LLC
 
 
 
 
11.2.11
GRAND RIVER ASEPTIC MANUFACTURING
 
 
 
 
11.2.12
RECIPHARM AB
 
 
 
 
11.2.13
PCI PHARMA SERVICES
 
 
 
 
11.2.14
CURIA GLOBAL, INC.
 
 
 
 
11.2.15
SIMTRA BIOPHARMA SOLUTIONS
 
 
 
 
11.2.16
PORTON
 
 
 
 
11.2.17
MABPLEX INTERNATIONAL CO. LTD.
 
 
 
 
11.2.18
CELLARES
 
 
12
APPENDIX
 
 
 
513
 
12.1
DISCUSSION GUIDE
 
 
 
 
12.2
KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
 
 
 
 
12.3
CUSTOMIZATION OPTIONS
 
 
 
 
12.4
RELATED REPORTS
 
 
 
 
12.5
AUTHOR DETAILS
 
 
 
LIST OF TABLES
 
 
 
 
 
TABLE 1
PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: INCLUSIONS AND EXCLUSIONS
 
 
 
 
TABLE 2
IMPACT ANALYSIS OF SUPPLY-SIDE AND DEMAND-SIDE FACTORS
 
 
 
 
TABLE 3
PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: RISK ANALYSIS
 
 
 
 
TABLE 4
PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: IMPACT ANALYSIS OF MARKET DYNAMICS
 
 
 
 
TABLE 5
GLP-1 PIPELINE, EXPECTED LAUNCH BY 2030
 
 
 
 
TABLE 6
ADC PIPELINE, EXPECTED LAUNCH BY 2030
 
 
 
 
TABLE 7
IMPENDING AND ONGOING PATENT EXPIRIES OF BLOCKBUSTER BIOLOGICS, 2023–2035
 
 
 
 
TABLE 8
LIST OF RECENTLY APPROVED INJECTABLES, 2022–2024
 
 
 
 
TABLE 9
CELL & GENE THERAPY-SPECIFIC CDMO EXPANSIONS, 2023–2025
 
 
 
 
TABLE 10
CELL & GENE THERAPY PIPELINE, EXPECTED LAUNCH BY 2030
 
 
 
 
TABLE 11
INDICATIVE PRICING ANALYSIS, BY SERVICE
 
 
 
 
TABLE 12
INDICATIVE PRICING ANALYSIS, BY REGION
 
 
 
 
TABLE 13
PRICING MODELS FOR CDMO SERVICES
 
 
 
 
TABLE 14
PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: ROLE OF COMPANIES IN SUPPLY CHAIN
 
 
 
 
TABLE 15
PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: ROLE OF COMPANIES IN ECOSYSTEM
 
 
 
 
TABLE 16
MANUFACTURING SITES OF KEY CDMOS
 
 
 
 
TABLE 17
LIST OF SITE EXPANSIONS FOR KEY CDMOS, 2023–2025
 
 
 
 
TABLE 18
CAPEX FOR SELECTED PUBLICLY LISTED KEY CDMOS, 2021–2024 (USD MILLION)
 
 
 
 
TABLE 19
NUMBER OF PATENTS FILED IN PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, 2014–2024
 
 
 
 
TABLE 20
PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: KEY CONFERENCES AND EVENTS, 2025–2026
 
 
 
 
TABLE 21
REGULATORY SCENARIO, BY COUNTRY
 
 
 
 
TABLE 22
NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
 
 
 
 
TABLE 23
EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
 
 
 
 
TABLE 24
ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
 
 
 
 
TABLE 25
LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
 
 
 
 
TABLE 26
MIDDLE EAST: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
 
 
 
 
TABLE 27
AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
 
 
 
 
TABLE 28
PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: PORTER’S FIVE FORCES ANALYSIS
 
 
 
 
TABLE 29
INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF PHARMACEUTICAL CONTRACT MANUFACTURING SERVICES (%)
 
 
 
 
TABLE 30
BUYING CRITERIA FOR PHARMACEUTICAL CONTRACT MANUFACTURING, BY END USER
 
 
 
 
TABLE 31
US-ADJUSTED RECIPROCAL TARIFF RATES
 
 
 
 
TABLE 32
PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 33
PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 34
PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY REGION, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 35
NORTH AMERICA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 36
EUROPE: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 37
ASIA PACIFIC: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 38
LATIN AMERICA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 39
MIDDLE EAST: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY REGION, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 40
GCC COUNTRIES: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 41
PHARMACEUTICAL API MANUFACTURING SERVICES MARKET, BY REGION, 2023–2030(USD BILLION)
 
 
 
 
TABLE 42
NORTH AMERICA: PHARMACEUTICAL API MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030(USD BILLION)
 
 
 
 
TABLE 43
EUROPE: PHARMACEUTICAL API MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030(USD BILLION)
 
 
 
 
TABLE 44
ASIA PACIFIC: PHARMACEUTICAL API MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030(USD BILLION)
 
 
 
 
TABLE 45
LATIN AMERICA: PHARMACEUTICAL API MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030(USD BILLION)
 
 
 
 
TABLE 46
MIDDLE EAST: PHARMACEUTICAL API MANUFACTURING SERVICES MARKET, BY REGION, 2023–2030(USD BILLION)
 
 
 
 
TABLE 47
GCC COUNTRIES: PHARMACEUTICAL API MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030(USD BILLION)
 
 
 
 
TABLE 48
PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030(USD BILLION)
 
 
 
 
TABLE 49
PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY REGION, 2023–2030(USD BILLION)
 
 
 
 
TABLE 50
NORTH AMERICA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030(USD BILLION)
 
 
 
 
TABLE 51
EUROPE: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030(USD BILLION)
 
 
 
 
TABLE 52
ASIA PACIFIC: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030(USD BILLION)
 
 
 
 
TABLE 53
LATIN AMERICA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030(USD BILLION)
 
 
 
 
TABLE 54
MIDDLE EAST: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY REGION, 2023–2030(USD BILLION)
 
 
 
 
TABLE 55
GCC COUNTRIES: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030(USD BILLION)
 
 
 
 
TABLE 56
PARENTERAL MANUFACTURING SERVICES MARKET, BY REGION, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 57
NORTH AMERICA: PARENTERAL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 58
EUROPE: PARENTERAL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 59
ASIA PACIFIC: PARENTERAL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 60
LATIN AMERICA: PARENTERAL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 61
MIDDLE EAST: PARENTERAL MANUFACTURING SERVICES MARKET, BY REGION, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 62
GCC COUNTRIES: PARENTERAL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 63
TABLET MANUFACTURING SERVICES MARKET, BY REGION, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 64
NORTH AMERICA: TABLET MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 65
EUROPE: TABLET MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 66
ASIA PACIFIC: TABLET MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 67
LATIN AMERICA: TABLET MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 68
MIDDLE EAST: TABLET MANUFACTURING SERVICES MARKET, BY REGION, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 69
GCC COUNTRIES: TABLET MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 70
CAPSULE MANUFACTURING SERVICES MARKET, BY REGION, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 71
NORTH AMERICA: CAPSULE MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 72
EUROPE: CAPSULE MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 73
ASIA PACIFIC: CAPSULE MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 74
LATIN AMERICA: CAPSULE MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 75
MIDDLE EAST: CAPSULE MANUFACTURING SERVICES MARKET, BY REGION, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 76
GCC COUNTRIES: CAPSULE MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 77
ORAL LIQUID MANUFACTURING SERVICES MARKET, BY REGION, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 78
NORTH AMERICA: ORAL LIQUID MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 79
EUROPE: ORAL LIQUID MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 80
ASIA PACIFIC: ORAL LIQUID MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 81
LATIN AMERICA: ORAL LIQUID MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 82
MIDDLE EAST: ORAL LIQUID MANUFACTURING SERVICES MARKET, BY REGION, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 83
GCC COUNTRIES: ORAL LIQUID MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 84
SEMI-SOLID MANUFACTURING SERVICES MARKET, BY REGION, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 85
NORTH AMERICA: SEMI-SOLID MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 86
EUROPE: SEMI-SOLID MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 87
ASIA PACIFIC: SEMI-SOLID MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 88
LATIN AMERICA: SEMI-SOLID MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 89
MIDDLE EAST: SEMI-SOLID MANUFACTURING SERVICES MARKET, BY REGION, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 90
GCC COUNTRIES: SEMI-SOLID MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 91
OTHER FDF MANUFACTURING SERVICES MARKET, BY REGION, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 92
NORTH AMERICA: OTHER FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 93
EUROPE: OTHER FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 94
ASIA PACIFIC: OTHER FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 95
LATIN AMERICA: OTHER FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 96
MIDDLE EAST: OTHER FDF MANUFACTURING SERVICES MARKET, BY REGION, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 97
GCC COUNTRIES: OTHER FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 98
PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR DRUG DEVELOPMENT SERVICES, BY REGION, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 99
NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR DRUG DEVELOPMENT SERVICES, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 100
EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR DRUG DEVELOPMENT SERVICES, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 101
ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR DRUG DEVELOPMENT SERVICES, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 102
LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR DRUG DEVELOPMENT SERVICES, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 103
MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR DRUG DEVELOPMENT SERVICES, BY REGION, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 104
GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR DRUG DEVELOPMENT SERVICES, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 105
PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS MANUFACTURING SERVICES, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 106
PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS MANUFACTURING SERVICES, BY REGION, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 107
NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS MANUFACTURING SERVICES, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 108
EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS MANUFACTURING SERVICES, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 109
ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS MANUFACTURING SERVICES, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 110
LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS MANUFACTURING SERVICES, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 111
MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS MANUFACTURING SERVICES, BY REGION, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 112
GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS MANUFACTURING SERVICES, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 113
PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS API MANUFACTURING SERVICES, BY REGION, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 114
NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS API MANUFACTURING SERVICES, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 115
EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS API MANUFACTURING SERVICES, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 116
ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS API MANUFACTURING SERVICES, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 117
LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS API MANUFACTURING SERVICES, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 118
MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS API MANUFACTURING SERVICES, BY REGION, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 119
GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS API MANUFACTURING SERVICES, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 120
PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS FDF MANUFACTURING SERVICES, BY REGION, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 121
NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS FDF MANUFACTURING SERVICES, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 122
EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS FDF MANUFACTURING SERVICES, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 123
ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS FDF MANUFACTURING SERVICES, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 124
LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS FDF MANUFACTURING SERVICES, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 125
MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS FDF MANUFACTURING SERVICES, BY REGION, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 126
GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS FDF MANUFACTURING SERVICES, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 127
PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR PACKAGING & LABELING SERVICES, BY REGION, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 128
NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR PACKAGING & LABELING SERVICES, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 129
EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR PACKAGING & LABELING SERVICES, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 130
ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR PACKAGING & LABELING SERVICES, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 131
LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR PACKAGING & LABELING SERVICES, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 132
MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR PACKAGING & LABELING SERVICES, BY REGION, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 133
GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR PACKAGING & LABELING SERVICES, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 134
PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR FILL-FINISH SERVICES, BY REGION, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 135
NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR FILL-FINISH SERVICES, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 136
EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR FILL-FINISH SERVICES, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 137
ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR FILL-FINISH SERVICES, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 138
LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR FILL-FINISH SERVICES, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 139
MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR FILL- FINISH SERVICES, BY REGION, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 140
GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR FILL-FINISH SERVICES, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 141
PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER SERVICES, BY REGION, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 142
NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER SERVICES, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 143
EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER SERVICES, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 144
ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER SERVICES, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 145
LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER SERVICES, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 146
MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER SERVICES, BY REGION, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 147
GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER SERVICES, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 148
PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 149
PHARMACEUTICAL MANUFACTURING SERVICES MARKET FOR SMALL MOLECULES, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 150
PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL MOLECULES, BY REGION, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 151
NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL MOLECULES, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 152
EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL MOLECULES, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 153
ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL MOLECULES, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 154
LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL MOLECULES, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 155
MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL MOLECULES, BY REGION, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 156
GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL MOLECULES, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 157
PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR HIGH-POTENCY SMALL MOLECULES, BY REGION, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 158
NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR HIGH-POTENCY SMALL MOLECULES, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 159
EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR HIGH-POTENCY SMALL MOLECULES, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 160
ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR HIGH-POTENCY SMALL MOLECULES, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 161
LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR HIGH-POTENCY SMALL MOLECULES, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 162
MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR HIGH-POTENCY SMALL MOLECULES, BY REGION, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 163
GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR HIGH POTENCY SMALL MOLECULES, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 164
PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OLIGONUCLEOTIDES AND SYNTHETIC PEPTIDES, BY REGION, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 165
NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OLIGONUCLEOTIDES AND SYNTHETIC PEPTIDES, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 166
EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OLIGONUCLEOTIDES AND SYNTHETIC PEPTIDES, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 167
ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OLIGONUCLEOTIDES AND SYNTHETIC PEPTIDES, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 168
LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OLIGONUCLEOTIDES AND SYNTHETIC PEPTIDES, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 169
MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OLIGONUCLEOTIDES AND SYNTHETIC PEPTIDES, BY REGION, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 170
GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OLIGONUCLEOTIDES AND SYNTHETIC PEPTIDES, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 171
PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR RADIOPHARMACEUTICAL MOLECULES, BY REGION, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 172
NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR RADIOPHARMACEUTICAL MOLECULES, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 173
EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR RADIOPHARMACEUTICAL MOLECULES, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 174
ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR RADIOPHARMACEUTICAL MOLECULES, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 175
LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR RADIOPHARMACEUTICAL MOLECULES, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 176
MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR RADIOPHARMACEUTICAL MOLECULES, BY REGION, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 177
GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR RADIOPHARMACEUTICAL MOLECULES, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 178
PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER SMALL MOLECULES, BY REGION, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 179
NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER SMALL MOLECULES, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 180
EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER SMALL MOLECULES, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 181
ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER SMALL MOLECULES, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 182
LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER SMALL MOLECULES, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 183
MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER SMALL MOLECULES, BY REGION, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 184
GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER SMALL MOLECULES, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 185
PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR LARGE MOLECULES, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 186
PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR LARGE MOLECULES, BY REGION, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 187
NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR LARGE MOLECULES, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 188
EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR LARGE MOLECULES, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 189
ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR LARGE MOLECULES, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 190
LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR LARGE MOLECULES, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 191
MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR LARGE MOLECULES, BY REGION, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 192
GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR LARGE MOLECULES, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 193
PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR MONOCLONAL ANTIBODIES, BY REGION, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 194
NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 195
EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 196
ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 197
LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 198
MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR MONOCLONAL ANTIBODIES, BY REGION, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 199
GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 200
PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR CELL & GENE THERAPIES, BY REGION, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 201
NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR CELL & GENE THERAPIES, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 202
EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR CELL & GENE THERAPIES, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 203
ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR CELL & GENE THERAPIES, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 204
LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR CELL & GENE THERAPIES, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 205
MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR CELL & GENE THERAPIES, BY REGION, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 206
GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR CELL & GENE THERAPIES, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 207
PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR ANTIBODY DRUG CONJUGATES, BY REGION, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 208
NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR ANTIBODY DRUG CONJUGATES, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 209
EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR ANTIBODY DRUG CONJUGATES, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 210
ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR ANTIBODY DRUG CONJUGATES, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 211
LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR ANTIBODY DRUG CONJUGATES, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 212
MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR ANTIBODY DRUG CONJUGATES, BY REGION, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 213
GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR ANTIBODY DRUG CONJUGATES, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 214
PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR VACCINES, BY REGION, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 215
NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR VACCINES, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 216
EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR VACCINES, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 217
ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR VACCINES, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 218
LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR VACCINES, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 219
MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR VACCINES, BY REGION, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 220
GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR VACCINES, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 221
PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR THERAPEUTIC PEPTIDES & PROTEINS, BY REGION, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 222
NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR THERAPEUTIC PEPTIDES & PROTEINS, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 223
EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR THERAPEUTIC PEPTIDES & PROTEINS, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 224
ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR THERAPEUTIC PEPTIDES & PROTEINS, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 225
LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR THERAPEUTIC PEPTIDES & PROTEINS, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 226
MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR THERAPEUTIC PEPTIDES & PROTEINS, BY REGION, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 227
GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR THERAPEUTIC PEPTIDES & PROTEINS, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 228
PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER LARGE MOLECULES, BY REGION, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 229
NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER LARGE MOLECULES, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 230
EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER LARGE MOLECULES, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 231
ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER LARGE MOLECULES, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 232
LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER LARGE MOLECULES, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 233
MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER LARGE MOLECULES, BY REGION, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 234
GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER LARGE MOLECULES, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 235
PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 236
PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIG PHARMACEUTICAL COMPANIES, BY REGION, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 237
NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIG PHARMACEUTICAL COMPANIES, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 238
EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIG PHARMACEUTICAL COMPANIES, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 239
ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIG PHARMACEUTICAL COMPANIES, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 240
LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIG PHARMACEUTICAL COMPANIES, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 241
MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIG PHARMACEUTICAL COMPANIES, BY REGION, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 242
GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIG PHARMACEUTICAL COMPANIES, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 243
PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL & MEDIUM-SIZED PHARMACEUTICAL COMPANIES, BY REGION, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 244
NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL & MEDIUM-SIZED PHARMACEUTICAL COMPANIES, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 245
EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL & MEDIUM-SIZED PHARMACEUTICAL COMPANIES, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 246
ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL & MEDIUM-SIZED PHARMACEUTICAL COMPANIES, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 247
LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL & MEDIUM-SIZED PHARMACEUTICAL COMPANIES, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 248
MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL & MEDIUM-SIZED PHARMACEUTICAL COMPANIES, BY REGION, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 249
GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL & MEDIUM-SIZED PHARMACEUTICAL COMPANIES, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 250
PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR GENERIC PHARMACEUTICAL COMPANIES, BY REGION, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 251
NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR GENERIC PHARMACEUTICAL COMPANIES, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 252
EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR GENERIC PHARMACEUTICAL COMPANIES, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 253
ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR GENERIC PHARMACEUTICAL COMPANIES, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 254
LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR GENERIC PHARMACEUTICAL COMPANIES, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 255
MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR GENERIC PHARMACEUTICAL COMPANIES, BY REGION, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 256
GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR GENERIC PHARMACEUTICAL COMPANIES, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 257
PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER END USERS, BY REGION, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 258
NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 259
EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 260
ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 261
LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 262
MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER END USERS, BY REGION, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 263
GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 264
PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY REGION, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 265
NORTH AMERICA: KEY MACROECONOMIC INDICATORS
 
 
 
 
TABLE 266
NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 267
NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 268
NORTH AMERICA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 269
NORTH AMERICA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 270
NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS MANUFACTURING SERVICES, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 271
NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 272
NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL MOLECULES, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 273
NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR LARGE MOLECULES, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 274
NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 275
US: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 276
US: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 277
US: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 278
US: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS MANUFACTURING SERVICES, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 279
US: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 280
US: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL MOLECULES, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 281
US: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR LARGE MOLECULES, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 282
US: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 283
CANADA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 284
CANADA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 285
CANADA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 286
CANADA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS MANUFACTURING SERVICES, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 287
CANADA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 288
CANADA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL MOLECULES, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 289
CANADA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR LARGE MOLECULES, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 290
CANADA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 291
EUROPE: KEY MACROECONOMIC INDICATORS
 
 
 
 
TABLE 292
EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 293
EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 294
EUROPE: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 295
EUROPE: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 296
EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS MANUFACTURING SERVICES, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 297
EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 298
EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL MOLECULES, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 299
EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR LARGE MOLECULES, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 300
EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 301
GERMANY: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 302
GERMANY: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 303
GERMANY: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 304
GERMANY: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS MANUFACTURING SERVICES, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 305
GERMANY: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 306
GERMANY: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL MOLECULES, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 307
GERMANY: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR LARGE MOLECULES, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 308
GERMANY: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 309
UK: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 310
UK: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 311
UK: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 312
UK: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS MANUFACTURING SERVICES, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 313
UK: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 314
UK: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL MOLECULES, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 315
UK: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR LARGE MOLECULES, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 316
UK: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 317
FRANCE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 318
FRANCE: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 319
FRANCE: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 320
FRANCE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS MANUFACTURING SERVICES, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 321
FRANCE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 322
FRANCE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL MOLECULES, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 323
FRANCE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR LARGE MOLECULES, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 324
FRANCE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 325
ITALY: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 326
ITALY: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 327
ITALY: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 328
ITALY: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS MANUFACTURING SERVICES, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 329
ITALY: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 330
ITALY: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL MOLECULES, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 331
ITALY: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR LARGE MOLECULES, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 332
ITALY: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 333
SWITZERLAND: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 334
SWITZERLAND: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 335
SWITZERLAND: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 336
SWITZERLAND: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS MANUFACTURING SERVICES, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 337
SWITZERLAND: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 338
SWITZERLAND: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL MOLECULES, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 339
SWITZERLAND: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR LARGE MOLECULES, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 340
SWITZERLAND: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 341
POLAND: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 342
POLAND: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 343
POLAND: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 344
POLAND: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS MANUFACTURING SERVICES, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 345
POLAND: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 346
POLAND: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL MOLECULES, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 347
POLAND: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR LARGE MOLECULES, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 348
POLAND: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 349
SPAIN: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 350
SPAIN: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 351
SPAIN: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 352
SPAIN: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS MANUFACTURING SERVICES, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 353
SPAIN: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 354
SPAIN: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL MOLECULES, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 355
SPAIN: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR LARGE MOLECULES, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 356
SPAIN: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 357
REST OF EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 358
REST OF EUROPE: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 359
REST OF EUROPE: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 360
REST OF EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS MANUFACTURING SERVICES, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 361
REST OF EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 362
REST OF EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL MOLECULES, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 363
REST OF EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR LARGE MOLECULES, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 364
REST OF EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 365
ASIA PACIFIC: KEY MACROECONOMIC INDICATORS
 
 
 
 
TABLE 366
ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 367
ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 368
ASIA PACIFIC: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 369
ASIA PACIFIC: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 370
ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS MANUFACTURING SERVICES, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 371
ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 372
ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL MOLECULES, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 373
ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR LARGE MOLECULES, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 374
ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 375
CHINA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 376
CHINA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 377
CHINA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 378
CHINA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS MANUFACTURING SERVICES, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 379
CHINA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 380
CHINA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL MOLECULES, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 381
CHINA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR LARGE MOLECULES, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 382
CHINA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 383
JAPAN: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 384
JAPAN: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 385
JAPAN: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 386
JAPAN: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS MANUFACTURING SERVICES, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 387
JAPAN: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 388
JAPAN: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL MOLECULES, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 389
JAPAN: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR LARGE MOLECULES, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 390
JAPAN: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 391
SOUTH KOREA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 392
SOUTH KOREA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 393
SOUTH KOREA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 394
SOUTH KOREA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS MANUFACTURING SERVICES, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 395
SOUTH KOREA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 396
SOUTH KOREA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL MOLECULES, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 397
SOUTH KOREA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR LARGE MOLECULES, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 398
SOUTH KOREA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 399
INDIA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 400
INDIA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 401
INDIA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 402
INDIA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS MANUFACTURING SERVICES, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 403
INDIA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 404
INDIA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL MOLECULES, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 405
INDIA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR LARGE MOLECULES, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 406
INDIA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 407
AUSTRALIA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 408
AUSTRALIA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 409
AUSTRALIA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 410
AUSTRALIA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS MANUFACTURING SERVICES, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 411
AUSTRALIA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 412
AUSTRALIA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL MOLECULES, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 413
AUSTRALIA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR LARGE MOLECULES, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 414
AUSTRALIA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 415
REST OF ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 416
REST OF ASIA PACIFIC: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 417
REST OF ASIA PACIFIC: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 418
REST OF ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS MANUFACTURING SERVICES, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 419
REST OF ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 420
REST OF ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL MOLECULES, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 421
REST OF ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR LARGE MOLECULES, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 422
REST OF ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 423
LATIN AMERICA: KEY MACROECONOMIC INDICATORS
 
 
 
 
TABLE 424
LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 425
LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 426
LATIN AMERICA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 427
LATIN AMERICA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 428
LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS MANUFACTURING SERVICES, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 429
LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 430
LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL MOLECULES, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 431
LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR LARGE MOLECULES, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 432
LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 433
BRAZIL: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 434
BRAZIL: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 435
BRAZIL: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 436
BRAZIL: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS MANUFACTURING SERVICES, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 437
BRAZIL: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 438
BRAZIL: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL MOLECULES, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 439
BRAZIL: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR LARGE MOLECULES, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 440
BRAZIL: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 441
MEXICO: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 442
MEXICO: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 443
MEXICO: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 444
MEXICO: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS MANUFACTURING SERVICES, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 445
MEXICO: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 446
MEXICO: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL MOLECULES, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 447
MEXICO: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR LARGE MOLECULES, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 448
MEXICO: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 449
REST OF LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 450
REST OF LATIN AMERICA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 451
REST OF LATIN AMERICA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 452
REST OF LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS MANUFACTURING SERVICES, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 453
REST OF LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 454
REST OF LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL MOLECULES, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 455
REST OF LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR LARGE MOLECULES, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 456
REST OF LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 457
MIDDLE EAST: KEY MACROECONOMIC INDICATORS
 
 
 
 
TABLE 458
MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY REGION, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 459
MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 460
MIDDLE EAST: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 461
MIDDLE EAST: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 462
MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS MANUFACTURING SERVICES, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 463
MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 464
MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL MOLECULES, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 465
MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR LARGE MOLECULES, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 466
MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 467
GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 468
GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 469
GCC COUNTRIES: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 470
GCC COUNTRIES: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 471
GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS MANUFACTURING SERVICES, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 472
GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 473
GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL MOLECULES, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 474
GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR LARGE MOLECULES, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 475
GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 476
KINGDOM OF SAUDI ARABIA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 477
KINGDOM OF SAUDI ARABIA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 478
KINGDOM OF SAUDI ARABIA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 479
KINGDOM OF SAUDI ARABIA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS MANUFACTURING SERVICES, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 480
KINGDOM OF SAUDI ARABIA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 481
KINGDOM OF SAUDI ARABIA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL MOLECULES, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 482
KINGDOM OF SAUDI ARABIA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR LARGE MOLECULES, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 483
KINGDOM OF SAUDI ARABIA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 484
UAE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 485
UAE: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 486
UAE: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 487
UAE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS MANUFACTURING SERVICES, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 488
UAE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 489
UAE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL MOLECULES, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 490
UAE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR LARGE MOLECULES, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 491
UAE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 492
REST OF GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 493
REST OF GCC COUNTRIES: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 494
REST OF GCC COUNTRIES: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 495
REST OF GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS MANUFACTURING SERVICES, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 496
REST OF GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 497
REST OF GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL MOLECULES, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 498
REST OF GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR LARGE MOLECULES, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 499
REST OF GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 500
REST OF MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 501
REST OF MIDDLE EAST: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 502
REST OF MIDDLE EAST: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 503
REST OF MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS MANUFACTURING SERVICES, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 504
REST OF MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 505
REST OF MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL MOLECULES, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 506
REST OF MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR LARGE MOLECULES, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 507
REST OF MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 508
AFRICA: KEY MACROECONOMIC INDICATORS
 
 
 
 
TABLE 509
AFRICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 510
AFRICA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 511
AFRICA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 512
AFRICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS MANUFACTURING SERVICES, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 513
AFRICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 514
AFRICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL MOLECULES, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 515
AFRICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR LARGE MOLECULES, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 516
AFRICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2023–2030 (USD BILLION) S
 
 
 
 
TABLE 517
OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, JANUARY 2022–AUGUST 2025
 
 
 
 
TABLE 518
PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: DEGREE OF COMPETITION
 
 
 
 
TABLE 519
PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: REGION FOOTPRINT
 
 
 
 
TABLE 520
PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: SERVICE FOOTPRINT
 
 
 
 
TABLE 521
PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: MOLECULE FOOTPRINT
 
 
 
 
TABLE 522
PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: DETAILED LIST OF KEY STARTUPS/SMES
 
 
 
 
TABLE 523
PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
 
 
 
 
TABLE 524
PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: SERVICE LAUNCHES, JANUARY 2022–JULY 2025
 
 
 
 
TABLE 525
PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: DEALS, JANUARY 2022–JULY 2025
 
 
 
 
TABLE 526
PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: EXPANSIONS, JANUARY 2022–JULY 2025
 
 
 
 
TABLE 527
THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
 
 
 
 
TABLE 528
THERMO FISHER SCIENTIFIC INC.: SERVICES OFFERED
 
 
 
 
TABLE 529
THERMO FISHER SCIENTIFIC INC.: SERVICE LAUNCHES, JANUARY 2022–JULY 2025
 
 
 
 
TABLE 530
THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2022–JULY 2025
 
 
 
 
TABLE 531
LONZA: COMPANY OVERVIEW
 
 
 
 
TABLE 532
LONZA: SERVICES OFFERED
 
 
 
 
TABLE 533
LONZA: DEALS, JANUARY 2022–JULY 2025
 
 
 
 
TABLE 534
LONZA: EXPANSIONS, JANUARY 2022–JULY 2025
 
 
 
 
TABLE 535
CATALENT, INC.: COMPANY OVERVIEW
 
 
 
 
TABLE 536
CATALENT, INC.: SERVICES OFFERED
 
 
 
 
TABLE 537
CATALENT, INC.: SERVICE LAUNCHES, JANUARY 2022–JULY 2025
 
 
 
 
TABLE 538
CATALENT, INC.: DEALS, JANUARY 2022–JULY 2025
 
 
 
 
TABLE 539
CATALENT, INC.: EXPANSIONS, JANUARY 2022–JULY 2025
 
 
 
 
TABLE 540
WUXI APPTEC: COMPANY OVERVIEW
 
 
 
 
TABLE 541
WUXI APPTEC: SERVICES OFFERED
 
 
 
 
TABLE 542
WUXI APPTEC: DEALS, JANUARY 2022–JULY 2025
 
 
 
 
TABLE 543
WUXI APPTEC: EXPANSIONS, JANUARY 2022–JULY 2025
 
 
 
 
TABLE 544
WUXI BIOLOGICS: COMPANY OVERVIEW
 
 
 
 
TABLE 545
WUXI BIOLOGICS: SERVICES OFFERED
 
 
 
 
TABLE 546
WUXI BIOLOGICS: SERVICE LAUNCHES, JANUARY 2022–JULY 2025
 
 
 
 
TABLE 547
WUXI BIOLOGICS: DEALS, JANUARY 2022–JULY 2025
 
 
 
 
TABLE 548
WUXI BIOLOGICS: EXPANSIONS, JANUARY 2022–JULY 2025
 
 
 
 
TABLE 549
WUXI BIOLOGICS: OTHER DEVELOPMENTS, JANUARY 2022–JULY 2025
 
 
 
 
TABLE 550
SAMSUNG BIOLOGICS: COMPANY OVERVIEW
 
 
 
 
TABLE 551
SAMSUNG BIOLOGICS: SERVICES OFFERED
 
 
 
 
TABLE 552
SAMSUNG BIOLOGICS: SERVICE LAUNCHES, JANUARY 2022–JUNE 2025
 
 
 
 
TABLE 553
SAMSUNG BIOLOGICS: DEALS, JANUARY 2022–JULY 2025
 
 
 
 
TABLE 554
SAMSUNG BIOLOGICS: EXPANSIONS, JANUARY 2022–JULY 2025
 
 
 
 
TABLE 555
BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY OVERVIEW
 
 
 
 
TABLE 556
BOEHRINGER INGELHEIM INTERNATIONAL GMBH: SERVICES OFFERED
 
 
 
 
TABLE 557
BOEHRINGER INGELHEIM INTERNATIONAL GMBH: DEALS, JANUARY 2022–JULY 2025
 
 
 
 
TABLE 558
BOEHRINGER INGELHEIM INTERNATIONAL GMBH: EXPANSIONS, JANUARY 2022–JULY 2025
 
 
 
 
TABLE 559
BOEHRINGER INGELHEIM INTERNATIONAL GMBH: OTHER DEVELOPMENTS, JANUARY 2022–JULY 2025
 
 
 
 
TABLE 560
EVONIK: COMPANY OVERVIEW
 
 
 
 
TABLE 561
EVONIK: SERVICES OFFERED
 
 
 
 
TABLE 562
EVONIK: DEALS, JANUARY 2022–JULY 2025
 
 
 
 
TABLE 563
EVONIK: EXPANSIONS, JANUARY 2022–JULY 2025
 
 
 
 
TABLE 564
FUJIFILM HOLDINGS CORPORATION: COMPANY OVERVIEW
 
 
 
 
TABLE 565
FUJIFILM HOLDINGS CORPORATION: SERVICES OFFERED
 
 
 
 
TABLE 566
FUJIFILM HOLDINGS CORPORATION: DEALS, JANUARY 2022–JULY 2025
 
 
 
 
TABLE 567
FUJIFILM HOLDINGS CORPORATION: EXPANSIONS, JANUARY 2022–JULY 2025
 
 
 
 
TABLE 568
ABBVIE INC.: COMPANY OVERVIEW
 
 
 
 
TABLE 569
ABBVIE INC.: SERVICES OFFERED
 
 
 
 
TABLE 570
ABBVIE INC.: DEALS, JANUARY 2022–JULY 2025
 
 
 
 
TABLE 571
ABBVIE INC.: EXPANSIONS, JANUARY 2022–JULY 2025
 
 
 
 
TABLE 572
SIEGFRIED HOLDING AG: COMPANY OVERVIEW
 
 
 
 
TABLE 573
SIEGFRIED HOLDING AG: SERVICES OFFERED
 
 
 
 
TABLE 574
SIEGFRIED HOLDING AG: DEALS, JANUARY 2022–JULY 2025
 
 
 
 
TABLE 575
SIEGFRIED HOLDING AG: EXPANSIONS, JANUARY 2022–JULY 2025
 
 
 
 
TABLE 576
MERCK KGAA: COMPANY OVERVIEW
 
 
 
 
TABLE 577
MERCK KGAA: SERVICES OFFERED
 
 
 
 
TABLE 578
MERCK KGAA: DEALS, JANUARY 2022–JULY 2025
 
 
 
 
TABLE 579
MERCK KGAA: EXPANSIONS, JANUARY 2022–JULY 2025
 
 
 
 
TABLE 580
ALMAC GROUP: COMPANY OVERVIEW
 
 
 
 
TABLE 581
ALMAC GROUP: SERVICES OFFERED
 
 
 
 
TABLE 582
ALMAC GROUP: DEALS, JANUARY 2022–JULY 2025
 
 
 
 
TABLE 583
ALMAC GROUP: EXPANSIONS, JANUARY 2022–JULY 2025
 
 
 
 
TABLE 584
CHARLES RIVER LABORATORIES: COMPANY OVERVIEW
 
 
 
 
TABLE 585
CHARLES RIVER LABORATORIES: SERVICES OFFERED
 
 
 
 
TABLE 586
CHARLES RIVER LABORATORIES: DEALS, JANUARY 2022–JULY 2025
 
 
 
 
TABLE 587
CHARLES RIVER LABORATORIES: EXPANSIONS, JANUARY 2022–JULY 2025
 
 
 
 
TABLE 588
ASYMCHEM INC.: COMPANY OVERVIEW
 
 
 
 
TABLE 589
ASYMCHEM INC.: SERVICES OFFERED
 
 
 
 
TABLE 590
ASYMCHEM INC.: DEALS, JANUARY 2022–JULY 2025
 
 
 
 
TABLE 591
ASYMCHEM INC.: EXPANSIONS, JANUARY 2022–JULY 2025
 
 
 
 
TABLE 592
VETTER: COMPANY OVERVIEW
 
 
 
 
TABLE 593
VETTER: SERVICES OFFERED
 
 
 
 
TABLE 594
VETTER: SERVICE LAUNCHES, JANUARY 2022–JULY 2025
 
 
 
 
TABLE 595
VETTER: DEALS, JANUARY 2022–JULY 2025
 
 
 
 
TABLE 596
VETTER: EXPANSIONS, JANUARY 2022–JULY 2025
 
 
 
 
TABLE 597
ALCAMI CORPORATION: COMPANY OVERVIEW
 
 
 
 
TABLE 598
ALCAMI CORPORATION: SERVICES OFFERED
 
 
 
 
TABLE 599
ALCAMI CORPORATION: DEALS, JANUARY 2022–JULY 2025
 
 
 
 
TABLE 600
ALCAMI CORPORATION: EXPANSIONS, JANUARY 2022–JULY 2025
 
 
 
 
TABLE 601
EUROFINS SCIENTIFIC: COMPANY OVERVIEW
 
 
 
 
TABLE 602
EUROFINS SCIENTIFIC: SERVICES OFFERED
 
 
 
 
TABLE 603
EUROFINS SCIENTIFIC: EXPANSIONS, JANUARY 2022–JUNE 2025
 
 
 
 
TABLE 604
PIRAMAL PHARMA SOLUTIONS: COMPANY OVERVIEW
 
 
 
 
TABLE 605
SYNGENE INTERNATIONAL LIMITED: COMPANY OVERVIEW
 
 
 
 
TABLE 606
CAMBREX CORPORATION: COMPANY OVERVIEW
 
 
 
 
TABLE 607
JUBILANT PHARMANOVA LIMITED: COMPANY OVERVIEW
 
 
 
 
TABLE 608
YUHAN CORPORATION: COMPANY OVERVIEW
 
 
 
 
TABLE 609
PIERRE FABRE LABORATORIES: COMPANY OVERVIEW
 
 
 
 
TABLE 610
PFIZER CENTREONE: COMPANY OVERVIEW
 
 
 
 
TABLE 611
DELPHARM: COMPANY OVERVIEW
 
 
 
 
TABLE 612
FRONTAGE LABS: COMPANY OVERVIEW
 
 
 
 
TABLE 613
SHARP SERVICES, LLC: COMPANY OVERVIEW
 
 
 
 
TABLE 614
GRAND RIVER ASEPTIC MANUFACTURING: COMPANY OVERVIEW
 
 
 
 
TABLE 615
RECIPHARM AB: COMPANY OVERVIEW
 
 
 
 
TABLE 616
PCI PHARMA SERVICES: COMPANY OVERVIEW
 
 
 
 
TABLE 617
CURIA GLOBAL, INC.: COMPANY OVERVIEW
 
 
 
 
TABLE 618
SIMTRA BIOPHARMA SOLUTIONS: COMPANY OVERVIEW
 
 
 
 
TABLE 619
PORTON: COMPANY OVERVIEW
 
 
 
 
TABLE 620
MABPLEX INTERNATIONAL CO. LTD.: COMPANY OVERVIEW
 
 
 
 
TABLE 621
CELLARES: COMPANY OVERVIEW
 
 
 
 
LIST OF FIGURES
 
 
 
 
 
FIGURE 1
PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SEGMENTATION AND REGIONAL SCOPE
 
 
 
 
FIGURE 2
PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: YEARS CONSIDERED
 
 
 
 
FIGURE 3
PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: RESEARCH DESIGN
 
 
 
 
FIGURE 4
PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: KEY DATA FROM SECONDARY SOURCES
 
 
 
 
FIGURE 5
PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: BREAKDOWN OF PRIMARY INTERVIEWS
 
 
 
 
FIGURE 6
PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2024
 
 
 
 
FIGURE 7
COMPANY REVENUE ANALYSIS-BASED ESTIMATION: BOTTOM-UP APPROACH, 2024
 
 
 
 
FIGURE 8
REVENUE SHARE ANALYSIS OF THERMO FISHER SCIENTIFIC INC., 2024
 
 
 
 
FIGURE 9
PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE VALIDATION FROM PRIMARY SOURCES
 
 
 
 
FIGURE 10
PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: TOP-DOWN APPROACH
 
 
 
 
FIGURE 11
PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: CAGR PROJECTIONS
 
 
 
 
FIGURE 12
PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: DATA TRIANGULATION
 
 
 
 
FIGURE 13
PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2025 VS. 2030 (USD BILLION)
 
 
 
 
FIGURE 14
PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2025 VS. 2030 (USD BILLION)
 
 
 
 
FIGURE 15
PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE, 2025 VS. 2030 (USD BILLION)
 
 
 
 
FIGURE 16
PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2025 VS. 2030 (USD BILLION)
 
 
 
 
FIGURE 17
PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY REGION, 2025–2030
 
 
 
 
FIGURE 18
RISING INVESTMENTS IN PHARMACEUTICAL R&D TO DRIVE MARKET
 
 
 
 
FIGURE 19
PHARMACEUTICAL MANUFACTURING SERVICES AND US TO LEAD NORTH AMERICAN MARKET IN 2025
 
 
 
 
FIGURE 20
SMALL MOLECULES SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
 
 
 
 
FIGURE 21
BIG PHARMACEUTICAL COMPANIES SEGMENT TO ACCOUNT FOR LARGEST MARKET SHARE DURING FORECAST PERIOD
 
 
 
 
FIGURE 22
CHINA TO HAVE LARGEST MARKET DURING FORECAST PERIOD
 
 
 
 
FIGURE 23
EMERGING MARKETS TO REGISTER HIGHER GROWTH DURING FORECAST PERIOD
 
 
 
 
FIGURE 24
PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
 
 
 
 
FIGURE 25
NEW REVENUE POCKETS FOR PLAYERS IN PHARMACEUTICAL CONTRACT MANUFACTURING MARKET
 
 
 
 
FIGURE 26
PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: VALUE CHAIN ANALYSIS
 
 
 
 
FIGURE 27
PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: SUPPLY CHAIN ANALYSIS
 
 
 
 
FIGURE 28
PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: ECOSYSTEM ANALYSIS
 
 
 
 
FIGURE 29
INVESTMENT AND FUNDING SCENARIO, 2023–2024
 
 
 
 
FIGURE 30
PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: PATENT ANALYSIS, JANUARY 2014–DECEMBER 2024
 
 
 
 
FIGURE 31
PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: PORTER’S FIVE FORCES ANALYSIS
 
 
 
 
FIGURE 32
INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY SERVICE
 
 
 
 
FIGURE 33
KEY BUYING CRITERIA FOR END USERS
 
 
 
 
FIGURE 34
ABBREVIATED NEW DRUG APPLICATION (ANDA) APPROVALS, 2020–2025
 
 
 
 
FIGURE 35
PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: AI USE CASES
 
 
 
 
FIGURE 36
NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SNAPSHOT
 
 
 
 
FIGURE 37
ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SNAPSHOT
 
 
 
 
FIGURE 39
PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SHARE ANALYSIS OF KEY PLAYERS, 2024
 
 
 
 
FIGURE 40
EV/EBITDA OF KEY VENDORS
 
 
 
 
FIGURE 41
YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
 
 
 
 
FIGURE 42
PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: BRAND/SERVICE COMPARISON
 
 
 
 
FIGURE 43
PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024
 
 
 
 
FIGURE 44
PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: COMPANY FOOTPRINT
 
 
 
 
FIGURE 45
PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024
 
 
 
 
FIGURE 46
THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2024)
 
 
 
 
FIGURE 47
LONZA: COMPANY SNAPSHOT (2024)
 
 
 
 
FIGURE 48
CATALENT, INC.: COMPANY SNAPSHOT (2023)
 
 
 
 
FIGURE 49
WUXI APPTEC: COMPANY SNAPSHOT (2024)
 
 
 
 
FIGURE 50
WUXI BIOLOGICS: COMPANY SNAPSHOT (2024)
 
 
 
 
FIGURE 51
SAMSUNG BIOLOGICS: COMPANY SNAPSHOT (2024)
 
 
 
 
FIGURE 52
BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY SNAPSHOT (2024)
 
 
 
 
FIGURE 53
EVONIK: COMPANY SNAPSHOT (2024)
 
 
 
 
FIGURE 54
FUJIFILM HOLDINGS CORPORATION: COMPANY SNAPSHOT (2024)
 
 
 
 
FIGURE 55
ABBVIE INC.: COMPANY SNAPSHOT (2024)
 
 
 
 
FIGURE 56
SIEGFRIED HOLDING AG: COMPANY SNAPSHOT (2024)
 
 
 
 
FIGURE 57
MERCK KGAA: COMPANY SNAPSHOT (2024)
 
 
 
 
FIGURE 58
ALMAC GROUP: COMPANY SNAPSHOT (2024)
 
 
 
 
FIGURE 59
CHARLES RIVER LABORATORIES: COMPANY SNAPSHOT (2024)
 
 
 
 
FIGURE 60
ASYMCHEM INC.: COMPANY SNAPSHOT (2024)
 
 
 
 
FIGURE 61
VETTER: COMPANY SNAPSHOT (2024)
 
 
 
 
FIGURE 62
EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2024)
 
 
 
 

Methodology

This research study extensively used secondary sources, directories, and databases to identify and collect valuable information to analyze the global pharmaceutical contract manufacturing market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and assess the growth prospects of the market. The global market size estimated through secondary research was then triangulated with inputs from primary research to arrive at the final market size.

Secondary Research

Secondary research was used mainly to identify and collect information for the extensive, technical, market-oriented, and commercial study of the pharmaceutical contract manufacturing market. The secondary sources used for this study include Indian Pharmaceutical Association (IPA), Pharmaceutical Research and Manufacturers of America (PhRMA), European Federation of Pharmaceutical Industries and Associations (EFPIA), Central Drugs Standard Control Organization (CDSCO), Indian Brand Equity Foundation (IBEF), European Medicines Agency (EMA), Pharma & Biopharma Outsourcing Association (PBOA), Generics and Biosimilars Initiative (GaBI), Pharma Times, Parenteral Drug Association (PDA), Indian Drug Manufacturers’ Association (IDMA), American Association of Pharmaceutical Scientists (AAPS), Global Cancer Observatory, American Chemical Society, National Center for Biotechnology Information, Eurostat, Food and Drug Administration (FDA), Biotechnology and Biological Sciences Research Council (BBSRC), Pharmaceutical Research and Manufacturers of America (PhRMA), World Journal of Pharmaceutical Sciences, research journals; corporate filings such as annual reports, SEC filings, investor presentations, and financial statements; press releases; trade, business, professional associations and among others. These sources were also used to obtain key information about major players, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives.

Primary Research

Following an initial assessment of the global pharmaceutical contract manufacturing market landscape through secondary research, comprehensive primary research was undertaken. This involved conducting in-depth interviews with market experts from the demand side, including stakeholders from pharmaceutical and biotechnology firms, CROs, CMOs, and academic and research institutions. Additionally, interviews were held with key supply-side participants, such as C-suite and senior executives, product managers, and marketing and sales leaders from prominent manufacturers, distributors, and channel partners. The research covered six major geographical regions: North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. Approximately 70% of the primary interviews were conducted with supply-side participants, while 30% involved demand-side experts. Data collection methods included structured questionnaires, email correspondence, online surveys, personal interviews, and telephonic discussions to understand the market dynamics comprehensively.

The following is a breakdown of the primary respondents:

Pharmaceutical Contract Manufacturing Market

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

Both bottom-up and top-down approaches were used to estimate and validate the total size of the pharmaceutical contract manufacturing market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

  • A list of the major global players operating in the pharmaceutical contract manufacturing market was generated.
  • The revenues generated from their pharmaceutical contract manufacturing product have been determined through annual reports and secondary sources (including paid databases)
  • The products were mapped according to the segments of the market. Percentage shares and splits were determined based on the revenue contributed to each segment. This was verified using secondary sources and by industry experts.
  • All assumptions, approaches, and individual shares/revenue estimates were validated through interviews with experts.

Global Pharmaceutical Contract Manufacturing Market: Bottom-up and Top-down Approach

Pharmaceutical Contract Manufacturing Market

Data Triangulation

After arriving at the market size from the estimation process explained above, the total market was divided into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

Market Definition

Pharmaceutical contract manufacturing organizations (CMOs) provide contract-based, comprehensive services, such as drug development and manufacturing. CMOs offer manufacturing services for active pharmaceutical ingredients (APIs) and finished dosage formulations (FDFs). Different aspects of contract manufacturing, such as drug development & manufacturing, formulation development, and commercial pharmaceutical & biopharmaceutical manufacturing, have been considered in this report.

Stakeholders

  • Contract Development & Manufacturing Organizations
  • Biotechnology and Pharmaceutical Companies
  • Academic and Research Institutions
  • Corporate Entities
  • Venture Capitalists
  • Regulatory Agencies
  • Industry Associations and Government Agencies
  • Pharmaceutical Distributors and Suppliers
  • Contract Research Organizations

Report Objectives

  • To define, describe, and forecast the global pharmaceutical contract manufacturing market based on the service, molecule, end user, and region
  • To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
  • To strategically analyze micromarkets1 with respect to individual growth trends, prospects, and contributions to the overall pharmaceutical contract manufacturing market
  • To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
  • To forecast the size of the market segments with respect to six main regions: North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
  • To profile the key players in the pharmaceutical contract manufacturing market and comprehensively analyze their service portfolios, market positions, and core competencies
  • To track and analyze competitive developments in the pharmaceutical contract manufacturing market, such as acquisitions, product launches, expansions, agreements, partnerships, and collaborations
  • To benchmark players within the pharmaceutical contract manufacturing market using the ‘Company Evaluation Matrix' framework, which analyzes market players based on various parameters within the broad categories of business strategy and product strategy

 

TABLE OF CONTENTS

METHODOLOGY

Need a Tailored Report?

Customize this report to your needs

Get 10% FREE Customization

Customize This Report
Fact checked
Cite this Research

Adjacent Markets

Request Bundle Reports

Personalize This Research

  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
Request A Free Customisation

Let Us Help You

  • What are the Known and Unknown Adjacencies Impacting the Pharmaceutical Contract Manufacturing Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
Customized Workshop Request
Forbes

Custom Market Research Services

We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements

Get 10% Free Customisation

Growth opportunities and latent adjacency in Pharmaceutical Contract Manufacturing Market

Kahlill

Feb, 2023

What will be the key challenges for business in the pharmaceutical contract manufacturing market in the near future?.

MnM Analyst

Jul, 2023

Key players in pharmaceutical contract manufacturing industry for North America region include:

  • Pfizer
  • Merck & Co., Inc.
  • Boehringer Ingelheim
  • AbbVie Inc.
  • Roche
  • Novartis
  • GlaxoSmithKline
  • Sanofi
  • AstraZeneca
  • Eli Lilly and Company among others
.

James

Jul, 2023

Who are the top key players in the pharmaceutical contract manufacturing market in North America?.

DMCA.com Protection Status